Herbal medicine Shakuyaku-kanzo-to reduces paclitaxel-induced painful peripheral neuropathy in mice

被引:44
作者
Hidaka, Takao [1 ,3 ,4 ]
Shima, Tomoka [1 ]
Nagira, Kiyofumi [1 ,4 ]
Ieki, Masahiro [1 ]
Nakamura, Takafumi [1 ]
Aono, Yukiko [2 ]
Kuraishi, Yasushi [2 ,4 ]
Arai, Takashi
Saito, Shigeru [1 ,4 ]
机构
[1] Toyama Univ, Fac Med, Dept Obstet & Gynecol, Toyama 9300194, Japan
[2] Toyama Univ, Fac Pharmaceut Sci, Dept Appl Pharmacol, Toyama 9300194, Japan
[3] Kurobe City Hosp, Dept Obstet & Gynecol, Toyama, Japan
[4] Toyama Univ, 21st Century COE Ctr Excellence Program, Toyama 9300194, Japan
关键词
Allodynia; Herbal medicine; Hyperalgesia; Muscle pain; Paclitaxel; Shakuyaku-kanzo-to; CELL LUNG-CANCER; METASTATIC BREAST-CANCER; QUALITY-OF-LIFE; PHASE-III TRIAL; OVARIAN-CANCER; MAINTENANCE HEMODIALYSIS; INTERGROUP TRIAL; ONCOLOGY-GROUP; STAGE-III; CISPLATIN;
D O I
10.1016/j.ejpain.2008.03.003
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objectives: Paclitaxel is widely used in cancer chemotherapy for the treatment of solid tumors such as breast, ovarian and lung cancer. However, it sometimes induces moderate to severe muscle pain, and impairs the patients' quality of life. An appropriate method for relieving this pain is not well established. Shakuyaku-kanzo-to, a herbal medicine, is known to relieve menstrual pain, muscle spasm, and muscle pain, and its effectiveness is expected. To ascertain the effectiveness of Shakuyaku-kanzo-to on paclitaxel-induced pain, we investigated the effects of Shakuyaku-kanzo-to and its constituent herbal medicines in a mouse model. Methods: Seven-week-old male ddY mice were used. To make a mouse model of paclitaxel-induced pain, different single, intraperitoneally injected doses of this drug were tested in various groups of mice, and the optimal dose was determined. To estimate the effects of Shakuyaku-kanzo-to, the constituent herbal medicines Shakuyaku and Kanzo, and loxoprofen sodium as a non-steroidal anti-inflammatory drug on paclitaxel-induced pain, mechanical allodynia and hyperalgesia of the hind paw were assessed. Results: Paclitaxel administered at a dose of 10 mg/kg or more produced allodynia and hyperalgesia; the time courses were similar to those of pain after paclitaxel administration in cancer patients. Shakuyaku-kanzo-to significantly relieved the allodynia and hyperalgesia induced by paclitaxel (10 mg/kg). Shakuyaku and Kanzo inhibited the allodynia and hyperalgesia to some extent, but not significantly, while loxoprofen sodium was without effects. Conclusions: A single administration of paclitaxel (10 mg/kg) produced allodynia and hyperalgesia in mice, suggesting that it could be used as an animal model resembling the painful conditions observed in humans medicated with this drug. Using this model. Shakuyaku-kanzo-to was shown to relieve paclitaxel-induced painful peripheral neuropathy. (C) 2008 European Federation of Chapters of the International Association for the Study of Pain. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:22 / 27
页数:6
相关论文
共 33 条
[1]   Paclitaxel in advanced non-small cell lung cancer - An alternative high-dose weekly schedule [J].
Akerley, W .
CHEST, 2000, 117 (04) :152S-155S
[2]   Description of a short-term Taxol®-induced nociceptive neuropathy in rats [J].
Authier, N ;
Gillet, JP ;
Fialip, J ;
Eschalier, A ;
Coudore, F .
BRAIN RESEARCH, 2000, 887 (02) :239-249
[3]   Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial [J].
Bonomi, P ;
Kim, KM ;
Fairclough, D ;
Cella, D ;
Kugler, J ;
Rowinsky, E ;
Jiroutek, M ;
Johnson, D .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :623-631
[4]  
CAVALETTI G, 1995, CANCER, V75, P1141, DOI 10.1002/1097-0142(19950301)75:5<1141::AID-CNCR2820750514>3.0.CO
[5]  
2-U
[6]   Role of protein kinase Cε and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat [J].
Dina, OA ;
Chen, X ;
Reichling, D ;
Levine, JD .
NEUROSCIENCE, 2001, 108 (03) :507-515
[7]   A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer [J].
du Bois, A ;
Lück, HJ ;
Meier, W ;
Adams, HP ;
Möbus, V ;
Costa, S ;
Bauknecht, T ;
Richter, B ;
Warm, M ;
Schröder, W ;
Olbricht, S ;
Nitz, U ;
Jackisch, C ;
Emons, G ;
Wagner, U ;
Kuhn, W ;
Pfisterer, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17) :1320-1330
[8]   PHASE-II STUDY AND LONG-TERM FOLLOW-UP OF PATIENTS TREATED WITH TAXOL FOR ADVANCED OVARIAN ADENOCARCINOMA [J].
EINZIG, AI ;
WIERNIK, PH ;
SASLOFF, J ;
RUNOWICZ, CD ;
GOLDBERG, GL .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) :1748-1753
[9]  
Fidias P, 2001, CLIN CANCER RES, V7, P3942
[10]   Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction [J].
Flatters, SJL ;
Bennett, GJ .
PAIN, 2006, 122 (03) :245-257